Epigenetic treatment of neuropsychiatric disorders: autism and schizophrenia
Moos, Walter H.
Pinkert, Carl A.
Irwin, Michael H.
Hoffman, Michelle E.
Faller, Douglas V.
MetadataShow full item record
Citation (published version)Walter H Moos, Eleni Maneta, Carl A Pinkert, Michael H Irwin, Michelle E Hoffman, Douglas V Faller, Kosta Steliou. 2016. "Epigenetic treatment of neuropsychiatric disorders: autism and schizophrenia." Drug Development Research Volume 77, Issue 2, pp. 53 - 72. https://doi.org/10.1002/ddr.21295
Neuropsychiatric disorders are a heterogeneous group of conditions that often share underlying mitochondrial dysfunction and biological pathways implicated in their pathogenesis, progression, and treatment. To date, these disorders have proven notoriously resistant to molecular-targeted therapies, and clinical options are relegated to interventional types, which do not address the core symptoms of the disease. In this review, we discuss emerging epigenetic-driven approaches using novel acylcarnitine esters (carnitinoids) that act on master regulators of antioxidant and cytoprotective genes and mitophagic pathways. These carnitinoids are actively transported, mitochondria-localizing, biomimetic coenzyme A surrogates of short-chain fatty acids, which inhibit histone deacetylase and may reinvigorate synaptic plasticity and protect against neuronal damage. We outline these neuroprotective effects in the context of treatment of neuropsychiatric disorders such as autism spectrum disorder and schizophrenia.
Please note: this work is permanently embargoed in OpenBU. No public access is forecasted for this item. To request private access, please click on the locked Download file link and fill out the appropriate web form.
Showing items related by title, author, creator and subject.
A latent class analysis of parental bipolar disorder: examining associations with offspring psychopathology Freed, Rachel D.; Tompson, Martha C.; Otto, Michael W.; Nierenberg, Andrew A.; Henin, Aude (ELSEVIER IRELAND LTD, 2015-12-15)Bipolar disorder (BD) is highly heterogeneous, and course variations are associated with patient outcomes. This diagnostic complexity challenges identification of patients in greatest need of intervention. Additionally, ...
Cassiello-Robbins, Clair; Barlow, David H. (WILEY, 2016-03-01)Anger plays a prominent definitional role in some psychological disorders currently widely scattered across DSM‐5 categories (e.g., intermittent explosive disorder, borderline personality disorder). But the presence and ...
Development of an integrated cognitive behavioral therapy for anxiety and opioid use disorder: Study protocol and methods McHugh, R. Kathryn; Votaw, Victoria R.; Barlow, David H.; Fitzmaurice, Garrett M.; Greenfield, Shelly F.; Weiss, Roger D. (ELSEVIER SCIENCE INC, 2017-09-01)Opioid use disorder is a highly disabling psychiatric disorder, and is associated with both significant functional disruption and risk for negative health outcomes such as infectious disease and fatal overdose. Even among ...